A proof of concept for structure-based vaccine design targeting RSV in humans-Reference-Cited by-同舟云学术

A proof of concept for structure-based vaccine design targeting RSV in humans

Published:2019-08-02 Issue:6452 Volume:365 Page:505-509
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Crank Michelle C.¹^ORCID,Ruckwardt Tracy J.¹^ORCID,Chen Man¹^ORCID,Morabito Kaitlyn M.¹^ORCID,Phung Emily¹²^ORCID,Costner Pamela J.¹,Holman LaSonji A.¹,Hickman Somia P.¹,Berkowitz Nina M.¹,Gordon Ingelise J.¹,Yamshchikov Galina V.¹,Gaudinski Martin R.¹,Kumar Azad¹,Chang Lauren A.¹^ORCID,Moin Syed M.¹,Hill Juliane P.¹,DiPiazza Anthony T.¹^ORCID,Schwartz Richard M.¹^ORCID,Kueltzo Lisa¹^ORCID,Cooper Jonathan W.¹,Chen Peifeng¹^ORCID,Stein Judith A.¹,Carlton Kevin¹^ORCID,Gall Jason G.¹,Nason Martha C.³^ORCID,Kwong Peter D.¹^ORCID,Chen Grace L.¹^ORCID,Mascola John R.¹^ORCID,McLellan Jason S.⁴^ORCID,Ledgerwood Julie E.¹,Graham Barney S.¹^ORCID,Novik Laura,Saunders Jamie,Mendoza Floreliz,Whalen William,Eshun Aba,Cunningham Jennifer,Wang Xiaolin,Hicks Renunda,Sitar Sandra,Hendel Cynthia Starr,Ola Abidemi,Requilman LaShawn,Tran Colin,Nguyen Thuy,Williams Pernell,Boyd Catina,Trofmenko Olga,Carter Cristina,Widge Alicia,

Affiliation:

1. Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

2. Institute for Biomedical Sciences, George Washington University, Washington, DC 20052, USA.

3. Biostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20852, USA.

4. Department of Molecular Biosciences, College of Natural Sciences, The University of Texas at Austin, Austin, TX 78712, USA.

Abstract

Building a better RSV vaccine Respiratory syncytial virus (RSV) causes severe respiratory disease, especially in infants and the elderly. However, attempts to produce effective human vaccines have largely been unsuccessful. Structure-based design has been used to generate an RSV fusion glycoprotein stabilized in its prefusion conformation (DS-Cav1). This immunogen is highly effective in mice and macaques. Crank et al. now report the results of a phase I vaccine clinical trial using the stabilized prefusion DS-Cav1 molecule. Four weeks after immunization, these vaccines elicited substantially more high-quality antibody titers than those typically generated using earlier RSV immunogens. The findings provide a proof of concept for how structural biology can contribute to precision vaccine design. Science , this issue p. 505

Funder

National Institute of Allergy and Infectious Diseases

Bill and Melinda Gates Foundation

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference32 articles.

1. RESPIRATORY SYNCYTIAL VIRUS DISEASE IN INFANTS DESPITE PRIOR ADMINISTRATION OF ANTIGENIC INACTIVATED VACCINE12

2. AN EPIDEMIOLOGIC STUDY OF ALTERED CLINICAL REACTIVITY TO RESPIRATORY SYNCYTIAL (RS) VIRUS INFECTION IN CHILDREN PREVIOUSLY VACCINATED WITH AN INACTIVATED RS VIRUS VACCINE

3. RESPIRATORY VIRUS IMMUNIZATION

4. FIELD EVALUATION OF A RESPIRATORY SYNCYTIAL VIRUS VACCINE AND A TRIVALENT PARAINFLUENZA VIRUS VACCINE IN A PEDIATRIC POPULATION1

5. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates

Cited by 198 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A molecular perspective for the development of antibodies against the human respiratory syncytial virus;Antiviral Research;2024-02

2. All Eyes on the Prefusion-Stabilized F Construct, but Are We Missing the Potential of Alternative Targets for Respiratory Syncytial Virus Vaccine Design?;Vaccines;2024-01-18

3. A neutralizing single-domain antibody that targets the trimer interface of the human metapneumovirus fusion protein;mBio;2024-01-16

4. Quantification of mRNA in Lipid Nanoparticles Using Mass Spectrometry;Analytical Chemistry;2024-01-08

5. RNA therapeutics for infectious diseases;Progress in Molecular Biology and Translational Science;2024